| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 663-666, Copyright © 1993 by American Association for Clinical Chemistry
WG John, MR Gray, DL Bates and JL Beacham
Department of Clinical Biochemistry, Royal London Hospital, Whitechapel, UK.
We describe a method for estimating hemoglobin A1c (HbA1c) with a commercially available enzyme immunoassay system. The method is based on microtiter plate technology, utilizing an antibody raised to hemoglobin, the epitope being the Amadori product of glucose plus the first eight amino acids on the N-terminal end of the beta chain of hemoglobin. The enzyme immunoassay displays good within-batch (CV 2.3- 2.4%) and between-batch (CV 2.6-5.0%) precision, and the results were not affected by different types of anticoagulant. The method was linear within the expected range of results and showed good correlation (r = 0.88-0.98) with established methods for estimating glycohemoglobin. Using this method, we obtained a reference interval of 2.8-4.9% (central 95%) for HbA1c in a nondiabetic population. The percentages of hemoglobin that were HbA1c in diabetics (6.86% +/- 2.51%) were significantly greater (P < 0.001) than in nondiabetics (3.46% +/- 0.52%).
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. Garcia-Alcala, A. Ruiz-Arguelles, and B. Cedillo-Carvallo Effect of the Method to Measure Levels of Glycated Hemoglobin on Individual Clinical Decisions: Comparison of an Immunoassay With High-Performance Liquid Chromatography Am J Clin Pathol, September 1, 2009; 132(3): 332 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Soedamah-Muthu, N. Chaturvedi, D. R. Witte, L. K. Stevens, M. Porta, J. H. Fuller, and for the EURODIAB Prospective Complications Study G Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study (PCS) Diabetes Care, July 1, 2008; 31(7): 1360 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Schram, C. G. Schalkwijk, A. H. Bootsma, J. H. Fuller, N. Chaturvedi, C. D.A. Stehouwer, and on behalf of the EURODIAB Prospective Complication Advanced Glycation End Products Are Associated With Pulse Pressure in Type 1 Diabetes: The EURODIAB Prospective Complications Study Hypertension, July 1, 2005; 46(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. van Hecke, J. M. Dekker, C. D.A. Stehouwer, B. C.P. Polak, J. H. Fuller, A. K. Sjolie, A. Kofinis, R. Rottiers, M. Porta, and N. Chaturvedi Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study Diabetes Care, June 1, 2005; 28(6): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A Anderson, G. R Ellis, L. M. Evans, K. Morris, Y. Y Chirkov, J. D Horowitz, S. K Jackson, A. Rees, M. J Lewis, and M. P Frenneaux Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 88 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Tesfaye, N. Chaturvedi, S. E.M. Eaton, J. D. Ward, C. Manes, C. Ionescu-Tirgoviste, D. R. Witte, J. H. Fuller, and the EURODIAB Prospective Complications Study Group Vascular Risk Factors and Diabetic Neuropathy N. Engl. J. Med., January 27, 2005; 352(4): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Soedamah-Muthu, N. Chaturvedi, M. Toeller, B. Ferriss, P. Reboldi, G. Michel, C. Manes, and J. H. Fuller Risk Factors for Coronary Heart Disease in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study Diabetes Care, February 1, 2004; 27(2): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sakurabayashi, T. Watano, S. Yonehara, K. Ishimaru, K. Hirai, T. Komori, and M. Yagi New Enzymatic Assay for Glycohemoglobin Clin. Chem., February 1, 2003; 49(2): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E Buyken, M. Toeller, G. Heitkamp, B. Karamanos, R. Rottiers, M. Muggeo, and J. H Fuller Glycemic index in the diet of European outpatients with type 1 diabetes: relations to glycated hemoglobin and serum lipids Am. J. Clinical Nutrition, March 1, 2001; 73(3): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chaturvedi, A.-K. Sjoelie, M. Porta, S. J. Aldington, J. H. Fuller, M. Songini, and E. M. Kohner Markers of Insulin Resistance Are Strong Risk Factors for Retinopathy Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, February 1, 2001; 24(2): 284 - 289. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Crook, J. C. Pickup, P. J. Lumb, F. Georgino, D. J. Webb, and J. H. Fuller Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes: The EURODIAB Complications Study Diabetes Care, February 1, 2001; 24(2): 316 - 322. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Evans, R. A. Anderson, J. Graham, G. R. Ellis, K. Morris, S. Davies, S. K. Jackson, M. J. Lewis, M. P. Frenneaux, and A. Rees Ciprofibrate Therapy Improves Endothelial Function and Reduces Postprandial Lipemia and Oxidative Stress in Type 2 Diabetes Mellitus Circulation, April 18, 2000; 101(15): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blincko and R. Edwards Non-separation assay for glycohemoglobin Clin. Chem., June 1, 1998; 44(6): 1302 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. John, F. Braconnier, K. Miedema, C. Aulesa, and G. Piras Evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer Clin. Chem., June 1, 1997; 43(6): 968 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holownia, E. Bishop, D. J. Newman, W. G. John, and C. P. Price Adaptation of latex-enhanced assay for percent glycohemoglobin to a Dade Dimension(R) analyzer Clin. Chem., January 1, 1997; 43(1): 76 - 84. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
